A new study published in the journal BMC Medicine showed that sitagliptin treatment helped preserve total femur T scores in women with type 2 diabetes compared to placebo, which suggest a protective effect on bone health.

Dipeptidyl peptidase-4 inhibitors (DPP4-Is) may preserve bone, according to experimental models, although there is a lack of clinical evidence and randomized studies that focus on bone outcomes. This trial was set to assess the safety and effectiveness of oral sitagliptin therapy for 52 weeks in enhancing bone outcomes in women with type 2 diabetes.

A total of 132 women with type 2 diabetes who were receiving metformin monotherapy and stable glycemic control were included in this study. The participants were chosen at random to receive sitagliptin or a placebo for 52

See Full Page